Onyedum Cajetan C, Alobu Isaac, Ukwaja Kingsley Nnanna
Department of Medicine, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.
National Tuberculosis and Leprosy Control Programme, Ministry of Health, Abakaliki, Ebonyi State, Nigeria.
PLoS One. 2017 Jul 13;12(7):e0180996. doi: 10.1371/journal.pone.0180996. eCollection 2017.
Drug-resistant tuberculosis (TB) undermines control efforts and its burden is poorly understood in resource-limited settings. We performed a systematic review and meta-analysis to provide an up-to-date summary of the extent of drug-resistant TB in Nigeria.
We searched PubMed, Scopus, Embase, HINARI, AJOL, the Cochrane library, Web of Science, and Google Scholar for reports published before January 31 2017, that included any resistance, mono-resistance or multidrug resistance to anti-TB drugs in Nigeria. Summary estimates were calculated using random effects models.
We identified 34 anti-TB drug resistance surveys with 8002 adult TB patients consisting of 2982 new and 5020 previously-treated cases. The prevalence rate of any drug resistance among new TB cases was 32.0% (95% CI 24.0-40.0%; 734/2892) and among previously-treated cases, the rate was 53.0% (95% CI 35.0-71.0%; 1467/5020). Furthermore, multidrug resistance among new and previously-treated cases was 6.0% (95% CI 4.0-8.0%;161/2502)and 32.0% (95%CI 20.0-44.0; 357/949), respectively. There was significant heterogeneity between the studies (p<0.001, I2 tests). The prevalence of drug-resistant TB varied according to methods of drug susceptibility testing and geographic region of Nigeria.
The burden of drug-resistant TB in Nigeria is high. We recommend that a national anti-TB drug resistance survey be carried out, and strategies for case detection and programmatic management of drug-resistant TB in Nigeria need to be strengthened.
耐多药结核病破坏了防控工作,在资源有限的环境中,其负担情况鲜为人知。我们进行了一项系统综述和荟萃分析,以提供尼日利亚耐多药结核病程度的最新总结。
我们检索了PubMed、Scopus、Embase、HINARI、AJOL、Cochrane图书馆、科学网和谷歌学术,查找2017年1月31日前发表的报告,这些报告包括尼日利亚抗结核药物的任何耐药性、单耐药或多耐药情况。使用随机效应模型计算汇总估计值。
我们确定了34项抗结核药物耐药性调查,涉及8002例成年结核病患者,其中包括2982例新发病例和5020例既往治疗病例。新发病例中任何药物耐药的患病率为32.0%(95%可信区间24.0 - 40.0%;734/2892),既往治疗病例中的患病率为53.0%(95%可信区间35.0 - 71.0%;1467/5020)。此外,新发病例和既往治疗病例中的多药耐药率分别为6.0%(95%可信区间4.0 - 8.0%;161/2502)和32.0%(95%可信区间20.0 - 44.0%;357/949)。研究之间存在显著异质性(p<0.001,I²检验)。耐多药结核病的患病率因药物敏感性检测方法和尼日利亚的地理区域而异。
尼日利亚耐多药结核病的负担很高。我们建议开展全国性抗结核药物耐药性调查,并加强尼日利亚耐药结核病病例检测和规划管理的策略。